Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 40.79% since last year same period to $325.72Mn in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 22.98% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit jumped 77.12% since last year same period to $165.16Mn in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 39.85% jump in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin jumped 25.81% since last year same period to 50.71% in the Q2 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 13.72% jump in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s price-to-earnings ratio after this Q2 2025 earnings stands at 16.52.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.43 - a 15.32% jump from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.43.

Halozyme Therapeutics, Inc.’s earning per share (EPS) jumped 69.23% since last year same period to 1.54 in the Q2 2025. This indicates that the Halozyme Therapeutics, Inc. has generated 69.23% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Halozyme Therapeutics, Inc.’s return on assets (ROA) stands at 0.21.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Halozyme Therapeutics, Inc.’s return on equity (ROE) stands at 1.79.